Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV000022111 | SCV001163237 | likely pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2023-11-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000022111 | SCV001394641 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2023-09-05 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 143 of the GALT protein (p.Ser143Leu). This variant is present in population databases (rs111033697, gnomAD 0.003%). This missense change has been observed in individual(s) with galactosemia (PMID: 9222760, 22944367; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 37358). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALT protein function. For these reasons, this variant has been classified as Pathogenic. |
Mayo Clinic Laboratories, |
RCV003480038 | SCV004226586 | likely pathogenic | not provided | 2022-12-21 | criteria provided, single submitter | clinical testing | PP3, PP4, PM2, PM3, PS4_moderate |
Natera, |
RCV001831617 | SCV002085206 | likely pathogenic | Galactosemia | 2019-11-04 | no assertion criteria provided | clinical testing |